Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$1.06 USD
-0.06 (-5.36%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.06 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Allogene Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ALLO 1.06 -0.06(-5.36%)
Will ALLO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALLO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALLO
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
ALLO: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
Other News for ALLO
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business ...
ALLO: JMP Securities Reiterates Market Perform Rating | ALLO Stock News
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday
Allogene Therapeutics (ALLO) Downgraded by JP Morgan to Neutral | ALLO Stock News
Allogene Therapeutics (ALLO) Faces Price Target Cut Amid Study Setback